Comparitive Study of Two Misoprostol Regimen in Early Pregnancy Termination
Information source: Hormozgan University of Medical Sciences
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Termination
Intervention: Misoprostol 400 micrograms (Drug); Misoprostol 800 micrograms (Drug)
Phase: N/A
Status: Completed
Sponsored by: Hormozgan University of Medical Sciences
Summary
The aim of this study is to compare two misoprostol regimen in pregnancy termination.
Clinical Details
Official title: A Comparative Study of Vaginal Misoprostol Two Dosing Regimen for First Trimester Pregnancy Termination in Patients Admitted at Bandarabbas in Shariati Hospital in 2009
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Primary outcome: Abortion
Secondary outcome: Duration of abortionAdverse Effects Need for surgery
Detailed description:
Studies on determining the optimal dosage for misoprostol in pregnancy termination are
continuing and still there is no evidence for ideal misoprostol regimen for pregnancy
termination. The aim of this study is to compare two misoprostol regimen in pregnancy
termination.
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Female.
Criteria:
Inclusion Criteria:
- All women who were candidates for early pregnancy termination because of fetal death
or other medical conditions
- Before 14th week of gestation calculated according LMP or first trimester sonography
Exclusion Criteria:
- Chorioamnionitis
- Hypersensitivity to prosstaglandins
- Past medical history of cardiovascular, kidney or liver or lung diseases
- Positive history for uterus pathologies
- suspicious to extra-uterus pregnancy
- sign and symptoms of uterus infection
- Molar pregnancy
Locations and Contacts
Hormozgan University of Medical Sciences, Bandar Abbas, Hormozgan 097145-3388, Iran, Islamic Republic of
Additional Information
Starting date: January 2012
Last updated: September 30, 2012
|